Page last updated: 2024-11-07

ro 8-0576

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

benserazide, levodopa drug combination: combination of L-Dopa and seryltrihydroxybenzylhydrazine; used in treatment of parkinsonism [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123809
SCHEMBL ID1134100
MeSH IDM0046533

Synonyms (13)

Synonym
benserazide, levodopa drug combination
modopar
ro 8-0576-7
ro 8-0576-12
ro 8-0576
l-tyrosine, 3-hydroxy-, mixt. with dl-serine 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide
37270-69-2
levopar
co-beneldopa
levobens-teva
SCHEMBL1134100
DTXSID80958414
3-hydroxytyrosine--2-amino-3-hydroxy-n-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazonic acid (1/1)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Adverse effects from Western drug-based medical intervention prevent long-term adherence to these therapies in many patients."( Evaluation on the efficacy and safety of Chinese herbal medication Xifeng Dingchan Pill in treating Parkinson's disease: study protocol of a multicenter, open-label, randomized active-controlled trial.
Ma, YZ; Shen, XM; Zhang, J, 2013
)
0.39
" The Unified Parkinson's Disease Rating Scale scores, TCM symptoms scores, quality of life, change of Madopar's dosage and the toxic and adverse effects of Madopar will be observed during a 3-month treatment period and through a further 6-month follow-up period."( Evaluation on the efficacy and safety of Chinese herbal medication Xifeng Dingchan Pill in treating Parkinson's disease: study protocol of a multicenter, open-label, randomized active-controlled trial.
Ma, YZ; Shen, XM; Zhang, J, 2013
)
0.39
" Reported adverse events were comparable between LB and LC users."( Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Kuoppamäki, M; Leinonen, M; Poewe, W, 2015
)
0.42
" In the safety evaluation, it was found that acupuncture combined with Madopar was associated with significantly fewer adverse effects including gastrointestinal reactions (RR=0."( Effectiveness and safety of acupuncture combined with Madopar for Parkinson's disease: a systematic review with meta-analysis.
Chen, L; Chen, W; Dong, H; Geng, G; Li, T; Liu, H; Zhan, S; Zhang, Z, 2017
)
0.46

Pharmacokinetics

ExcerptReferenceRelevance
" The present study, therefore, compared single dose kinetics and pharmacodynamic effects of three dosages of L-dopa/bensearazid-s."( [Slow-release L-dopa vs. standard L-dopa in Parkinson patients in various stages of the disease. Studies of pharmacokinetics and motor effectiveness].
Baas, H; Bergemann, N; Fischer, PA, 1994
)
0.29
" Plasma concentrations of levodopa and 3-O-methyldopa were measured by high-performance liquid chromatography for pharmacokinetic evaluation."( Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
Crevoisier, C; Metzger, B; Monreal, A; Nilsen, T, 2003
)
0.32
" Pharmacokinetic parameters were calculated for both treatments."( The effect of Madopar on the pharmacokinetics of ropinirole in healthy Chinese volunteers.
Bi, LL; Chen, XY; Jia, YY; Luo, XX; Wen, AD; Zhong, DF, 2007
)
0.34
" Pharmacokinetic parameters C(max), t(max), t(1/2z), mean residence time (MRT), AUC(0-tau), AUC(0-infinity), CL(z)/F and V(z)/F were determined under the non-compartmental model."( Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa).
Hang, TJ; Jia, L; Song, M; Wen, AD; Xu, XF; Yang, L; Zhang, TT, 2009
)
0.35
" For talipexole hydrochloride, there were no significant differences in the pharmacokinetic values between the two administrations."( Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa).
Hang, TJ; Jia, L; Song, M; Wen, AD; Xu, XF; Yang, L; Zhang, TT, 2009
)
0.35
"The aims of the present study were to investigate the pharmacokinetic and pharmacodynamic (pk/pd) relationship of levodopa (l-dopa) in patients with advanced Parkinson disease (PD) and also to evaluate the effect of tolcapone on the pk/pd analysis of l-dopa in 1 patient with severe dyskinesias and fluctuations."( Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E, 2010
)
0.36
" The dispersible levodopa/benserazide formulation showed earlier time to Cmax and significantly higher Cmax for levodopa in plasma compared to the microtablets."( Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers.
Aquilonius, SM; Bäckström, T; Ehrnebo, M; Gomes-Trolin, C; Lewander, T; Nyholm, D; Nyström, C; Panagiotidis, G,
)
0.13
"The new levodopa/carbidopa microtablets had a pharmacokinetic profile that would allow for a convenient switch of therapy from standard tablets."( Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers.
Aquilonius, SM; Bäckström, T; Ehrnebo, M; Gomes-Trolin, C; Lewander, T; Nyholm, D; Nyström, C; Panagiotidis, G,
)
0.13
" Half-life was 58."( L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB, 2012
)
0.38
" L-DOPA t(max) and half-life are also similar to those reported in human."( L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB, 2012
)
0.38
" The main levodopa pharmacodynamic variables were the maximum percentage increase in tapping frequency over baseline values (ΔTapmax %) and the area under the tapping effect-time curve (AUCTap)."( Pharmacodynamics of a low subacute levodopa dose helps distinguish between multiple system atrophy with predominant Parkinsonism and Parkinson's disease.
Calandra-Buonaura, G; Capellari, S; Contin, M; Cortelli, P; Doria, A; Guaraldi, P; Lopane, G; Martinelli, P, 2016
)
0.43
"To compare the levodopa/carbidopa (LC) and levodopa/benserazide (LB) pharmacokinetic profiles following repeated doses of opicapone (OPC) administered apart from levodopa."( Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.
Almeida, L; Bonifácio, MJ; Falcão, A; Fauchoux, N; Loureiro, AI; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Sicard, É; Soares-da-Silva, P, 2017
)
0.46
"While several generic preparations of levodopa/carbidopa and levodopa/benserazide (LBD) are currently available, pharmacokinetic (PK) equivalence and therapeutic equivalence studies with levodopa generics are not available in Italy."( Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar).
Alessandroni, J; Bonassi, S; Bravi, D; Casali, M; Fossati, C; Grassini, P; Ialongo, C; Onofrj, M; Radicati, FG; Stocchi, F; Torti, M; Vacca, L, 2019
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
"In an open study 25 depressed patients were treated with L-5-hydroxytryptophan (L-5-HTP) either alone or in combination with a peripheral decarboxylase inhibitor."( L-5-hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression.
Battegay, R; Gastpar, M; Zmilacher, K, 1988
)
0.27
"Fifty cases in a treatment group were treated by acupuncture combined with madopar, and 30 cases in a control group treated by madopar only."( Fifty cases of Parkinson's disease treated by acupuncture combined with madopar.
Ren, XM, 2008
)
0.35
"To evaluate the effectiveness and safety of acupuncture combined with Madopar for the treatment of Parkinson's disease (PD), compared to the use of Madopar alone."( Effectiveness and safety of acupuncture combined with Madopar for Parkinson's disease: a systematic review with meta-analysis.
Chen, L; Chen, W; Dong, H; Geng, G; Li, T; Liu, H; Zhan, S; Zhang, Z, 2017
)
0.46
" Meta-analyses showed that acupuncture combined with Madopar for the treatment of PD can significantly improve the clinical effectiveness compared with Madopar alone (RR=1."( Effectiveness and safety of acupuncture combined with Madopar for Parkinson's disease: a systematic review with meta-analysis.
Chen, L; Chen, W; Dong, H; Geng, G; Li, T; Liu, H; Zhan, S; Zhang, Z, 2017
)
0.46
"Acupuncture combined with Madopar appears, to some extent, to improve clinical effectiveness and safety in the treatment of PD, compared with Madopar alone."( Effectiveness and safety of acupuncture combined with Madopar for Parkinson's disease: a systematic review with meta-analysis.
Chen, L; Chen, W; Dong, H; Geng, G; Li, T; Liu, H; Zhan, S; Zhang, Z, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
" The negative aspects of Madopar HBS are a lower bioavailability that means a dosage increase and a longer latency for the therapeutic response in the morning."( Long-term treatment with Madopar HBS in parkinsonians with fluctuations.
Aljanati, R; Buzó, R; Caamaño, JL; Chouza, C; De Medina, O; Fernandez, A; Plachín, V; Romero, S; Scaramelli, A, 1990
)
0.28
" The clinical response to Madopar HBS was delayed and brief; the relative bioavailability was only 50%."( Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
Jenner, P; Malcolm, SL; Marion, MH; Marsden, CD; Quinn, NP; Stocchi, F, 1987
)
0.27
" In comparison with standard Madopar the rate of absorption is reduced, providing lower peak concentrations of L-dopa."( Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid on the absorption of Madopar HBS in volunteers.
Allen, JG; Bird, H; Malcolm, SL; Marion, MH; Marsden, CD; O'Leary, CG; Quinn, NP, 1987
)
0.27
" The mean relative bioavailability (versus standard Madopar) was 58 and 67% (value normalized to dose) for one and two HBS capsules, respectively."( Bioavailability of L-dopa after Madopar HBS administration in healthy volunteers.
Crevoisier, C; Da Prada, M; Hoevels, B; Zürcher, G, 1987
)
0.27
" There were no statistically significant differences in the cumulative amount absorbed of drug and the absorption rate in the presence or absence of Madopar."( Lack of an effect of Madopar on the disposition of tolcapone and its 3-O-methylated metabolite in rats.
Fukazawa, H; Funaki, T; Kuruma, I; Onodera, H; Tagami, C; Tsukamoto, Y; Ushiyama, N, 1995
)
0.29
" Due to a lower bioavailability of the slow release formulation--the latter is based on the "hydrodynamically balanced system" (HBS)--, the patients remained initially on their time schedule of drug intake but received a higher dose of L-DOPA slow release compared to the preceding L-DOPA standard therapy."( [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
Eichhorn, TE; Kohnen, R; Oertel, WH; Poewe, W; Schrag, A; Selzer, R; Trenkwalder, C, 1995
)
0.29
" The relative bioavailability (Madopar DR vs."( Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
Crevoisier, C; Metzger, B; Monreal, A; Nilsen, T, 2003
)
0.32
"The aim of the study was to investigate the potential effect of short, moderate intensity (≤70% maximum heart rate) cyclette exercise on levodopa (LD)/dopa decarboxylase inhibitor bioavailability and motor response in a subgroup of Parkinson disease (PD) patients presenting a moderate-to-severe delay in fasting morning LD dose absorption and matched motor response."( The effect of a clinically practical exercise on levodopa bioavailability and motor response in patients with Parkinson disease.
Albani, F; Baruzzi, A; Contin, M; Lopane, G; Martinelli, P; Scaglione, C,
)
0.13
"The aim of this study was to evaluate the fasting bioavailability of a new generic formulation of levodopa 200 mg/benserazide 50 mg tablets (test) and compare this generic formulation with the branded formulation (reference) to meet regulatory criteria for marketing the test product in Argentina."( Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study.
Assefi, AR; Bertuola, R; Czerniuk, P; Di Girolamo, G; Keller, GA; Spatz, JG, 2011
)
0.37
"To compare bioavailability and pharmacokinetics of single doses of 3 different levodopa formulations given orally in healthy volunteers."( Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers.
Aquilonius, SM; Bäckström, T; Ehrnebo, M; Gomes-Trolin, C; Lewander, T; Nyholm, D; Nyström, C; Panagiotidis, G,
)
0.13
" However, bioavailability of drugs varies between species and it is unknown how plasma L-DOPA levels providing therapeutic benefit in the non-human primate compare to those having similar actions in PD patients."( L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB, 2012
)
0.38
"Opicapone, as once-daily oral evening regimen and/or 1 h apart from levodopa therapy, increases the bioavailability of levodopa associated with its pronounced, long-lasting and sustained catechol-O-methyltransferase inhibition."( Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.
Almeida, L; Bonifácio, MJ; Falcão, A; Fauchoux, N; Loureiro, AI; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Sicard, É; Soares-da-Silva, P, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
" The negative aspects of Madopar HBS are a lower bioavailability that means a dosage increase and a longer latency for the therapeutic response in the morning."( Long-term treatment with Madopar HBS in parkinsonians with fluctuations.
Aljanati, R; Buzó, R; Caamaño, JL; Chouza, C; De Medina, O; Fernandez, A; Plachín, V; Romero, S; Scaramelli, A, 1990
)
0.28
" The equivalent L-dopa dosage had to be increased by 56% (29-100%) with Madopar HBS while mean dopamine levels increased in four patients (by 47-257%) without the occurrence of peripheral side-effects."( Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
Ceballos-Baumann, AO; Eckert, W; von Kummer, R; Weicker, H, 1990
)
0.28
" In 13 patients a considerable diminution in nocturnal akinesia and in the frequency of waking up was reached with a mean dosage of 308 mg of Madopar HBS."( Madopar HBS in nocturnal symptoms of Parkinson's disease.
Jansen, EN; Meerwaldtt, JD, 1990
)
0.28
" The results suggest, the BH4 in the dosage used, is not effective in the treatment of Parkinson's disease."( Tetrahydrobiopterin and Parkinson's disease.
Dissing, IC; Gerdes, AM; Güttler, F; Lou, H; Lykkelund, C; Pakkenberg, H; Rasmussen, V, 1989
)
0.28
" The optimal therapeutic dosage of Sinemet CR was equal to that of Madopar HBS but 12% higher than that of standard Madopar."( Treatment of early Parkinson's disease with controlled-release levodopa preparations.
Rinne, JO; Rinne, UK, 1989
)
0.28
" Plasma ALAAD 2 hours after dosing was normal in Groups I and II."( Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
Boomsma, F; Hovestadt, A; Man in 't Veld, AJ; Meerwaldt, JD; Schalekamp, MA, 1989
)
0.28
" The model is then used to optimize the dosage regimen for each patient individually (according to the clinical particularities and needs of each patient) with respect to an objective function which includes the symptoms dynamically and the total amount of levodopa which is to be administered."( Optimization of symptomatic therapy in Parkinson's disease.
Albani, C; Hacisalihzade, SS; Mansour, M, 1989
)
0.28
" Even better results could be accomplished in an extended trial attempting to establish the best dosage ratio of the combination, possibly admitting increased dosage."( A combined regimen of subcutaneous lisuride and oral Madopar HBS in Parkinson's disease.
Aljanati, R; Caamaño, JL; Chouza, C; de Medina, O; Romero, S; Scaramelli, A, 1988
)
0.27
" During the first month the dosage titration was aimed at finding the optimal therapeutic effect."( Clinical trial of Madopar HBS in parkinsonian patients with fluctuating drug response after long-term levodopa therapy.
Aymard, N; Holzer, J; Rondot, P; Ziegler, M, 1987
)
0.27
"Madopar HBS (125 mg) is a controlled-release dosage form with 100 mg L-dopa and 25 mg benserazide."( The hydrodynamically balanced system: a novel principle of controlled drug release.
Erni, W; Held, K, 1987
)
0.27
" At the beginning the patients were switched from standard Madopar to Madopar HBS, initially keeping constant L-dopa dosage and the number of daily doses."( Open clinical study of Madopar HBS.
Ludin, HP, 1987
)
0.27
" However, with the new formulation the dosage had to be increased by 86% on average as compared with standard Madopar."( Treatment of parkinsonian conditions with a controlled-release form of levodopa--preliminary study.
D'Andrea, G; Durisotti, C; Ferro-Milone, F; Lion, P; Lorizio, A; Nordera, GP, 1987
)
0.27
" For the first few days (up to 1 week) dosage and number of daily intakes of HBS were the same as those of the standard formulation."( Preliminary experience with Madopar HBS: clinical observations and plasma levodopa concentrations.
Baas, H; Fischer, PA, 1987
)
0.27
" The overall increase in dosage of levodopa with Madopar HBS was 54% in comparison with the initial standard Madopar dosage."( Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment.
Heersema, T; Jansen, EN; Meerwaldt, JD; Speelman, JD; van Manen, J, 1987
)
0.27
" The frequency of drug intake was unaltered but daily dosage could be increased by 30% without increasing severity of abnormal movements to a similar degree."( [Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease].
Aymard, N; Holzer, J; Rondot, P; Ziegler, M, 1987
)
0.27
" In 13 patients a considerable diminution in nocturnal akinesia and in the frequency of waking up was reached with a mean dosage of 308 mg of Madopar HBS."( Madopar HBS in Parkinson patients with nocturnal akinesia.
Jansen, EN; Meerwaldt, JD, 1988
)
0.27
" Although the bioavailability after oral dosing is reduced as compared with standard Madopar (60-70%), this difference seems to be due to incomplete absorption rather than altered disposition of the drug."( Single-dose pharmacokinetics of Madopar HBS in patients and effect of food and antacid on the absorption of Madopar HBS in volunteers.
Allen, JG; Bird, H; Malcolm, SL; Marion, MH; Marsden, CD; O'Leary, CG; Quinn, NP, 1987
)
0.27
" At the end of the dosage adaptation phase (9 weeks) most patients improved; in patients with 'on-off' phenomenon, parkinsonism became less severe, on periods were longer, and fluctuations decrease; end-of-dose impairment resolved in 4 patients."( Substitution of standard Madopar by Madopar HBS in parkinsonians with fluctuations.
Aljanati, R; Caamano, JL; Chouza, C; de Medina, O; Gonzales Panizza, V; Romero, S; Scarmelli, A, 1987
)
0.27
" The dosage was adjusted until optimal response was obtained."( Madopar HBS: slow-release levodopa and benserazide in parkinsonian patients presenting marked fluctuations in symptoms on standard L-dopa treatment.
Dupont, E; Hansen, E; Jensen, NO; Mikkelsen, B; Mikkelsen, BO, 1987
)
0.27
" In all patients of the first group, after 3 months on stable 'optimal' dosage schedule, the previous L-dopa treatment was abruptly replaced, dose for dose, from one day to another by Madopar HBS, a new controlled-release form of Madopar."( Therapeutic value of Madopar HBS: judgment after 2 years experience.
Siegfried, J, 1987
)
0.27
" Following effective stereotaxic surgery, drug therapy should be continued with reduced dosage of the drugs."( [Combined (surgical and drug) therapy of parkinsonism].
Iadgarov, IS; Kandel', EI, 1984
)
0.27
" PRL increase after benserazide was compared with PRL response after carbidopa at the same dosage in untreated parkinsonian patients."( Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
Agnoli, A; Baldassarre, M; D'Urso, R; De Giorgio, G; Falaschi, P; Rocco, A; Ruggieri, S, 1982
)
0.26
" Two dosage strengths are available: 100 mg levodopa plus 25 mg benserazide and 50 mg levodopa plus 12."( [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].
Dessibourg, CA; Gachoud, JP, 1995
)
0.29
" A three times greater dosage of L-dopa-s."( [Slow-release L-dopa vs. standard L-dopa in Parkinson patients in various stages of the disease. Studies of pharmacokinetics and motor effectiveness].
Baas, H; Bergemann, N; Fischer, PA, 1994
)
0.29
" The drugs were dosed according to the individual need of the patients."( Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients.
Andersen, A; Boas, J; Boisen, E; Borgmann, R; Buch, D; Dupont, E; Helgetveit, AC; Kjaer, MO; Kristensen, TN; Mikkelsen, B; Pakkenberg, H; Presthus, J; Stien, R; Worm-Petersen, J, 1996
)
0.29
" As a consequence, levodopa dosage might be increased and the interdose interval progressively shortened."( Clinical implications of sustained dopaminergic stimulation.
Barbato, L; Berardelli, A; Bonamartini, A; Manfredi, M; Patsalos, PN; Ruggieri, S; Stocchi, F, 1994
)
0.29
" Daily levodopa dosage requirements decreased significantly."( Highlights of the North American and European experiences.
Goetz, CG, 1998
)
0.3
" L-DOPA was used in the form of the drug madopar in dosage of 25,5 mg/kg of body mass daily."( [Influence of L-DOPA on rat brain depending on individual behavioral features].
Gershteĭn, LM; Sergutina, AV, 2004
)
0.32
" The microtablets are intended for individualized dosing of levodopa/carbidopa in Parkinson disease by means of an electronic dose dispenser with a built-in diary for symptom registration."( Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers.
Aquilonius, SM; Bäckström, T; Ehrnebo, M; Gomes-Trolin, C; Lewander, T; Nyholm, D; Nyström, C; Panagiotidis, G,
)
0.13
" The Unified Parkinson's Disease Rating Scale scores, TCM symptoms scores, quality of life, change of Madopar's dosage and the toxic and adverse effects of Madopar will be observed during a 3-month treatment period and through a further 6-month follow-up period."( Evaluation on the efficacy and safety of Chinese herbal medication Xifeng Dingchan Pill in treating Parkinson's disease: study protocol of a multicenter, open-label, randomized active-controlled trial.
Ma, YZ; Shen, XM; Zhang, J, 2013
)
0.39
" Rats were dosed orally with Tozadenant, a selective A2A receptor antagonist, and three different doses of Radiprodil, an NR2B-selective NMDA receptor antagonist."( Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs.
De Wolf, C; Downey, P; Michel, A; Scheller, D; Schwarting, R; Van Damme, X, 2015
)
0.42
"  Madopar dosage was maintained in both groups."( The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia.
Cao, LD; Guo, G; Wu, QY; Xu, S, 2016
)
0.43
"Despite extensive research in the field of gastroretentive dosage forms, this "holy grail" of oral drug delivery yet remained an unmet goal."( Influence of Postprandial Intragastric Pressures on Drug Release from Gastroretentive Dosage Forms.
Hoppe, M; Koziolek, M; Schneider, F; Weitschies, W, 2018
)
0.48
" As LD/BH sustained release suspension can synchronize sustained release of multiple active ingredients by oral administration, the suspension presents promising oral dosage forms for geriatric patients with PD."( Development, Optimization, and Evaluation In Vitro/In Vivo of Oral Liquid System for Synchronized Sustained Release of Levodopa/Benserazide.
Ding, YP; Lai, WL; Liu, HF; Qu, Y; Wang, L; Xin, YR; Xu, Y; Zhu, FQ; Zhu, Y, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (200)

TimeframeStudies, This Drug (%)All Drugs %
pre-199065 (32.50)18.7374
1990's36 (18.00)18.2507
2000's23 (11.50)29.6817
2010's67 (33.50)24.3611
2020's9 (4.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.06 (24.57)
Research Supply Index5.63 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials63 (29.44%)5.53%
Reviews7 (3.27%)6.00%
Case Studies29 (13.55%)4.05%
Observational2 (0.93%)0.25%
Other113 (52.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]